Stockscreener 앱 받기
121.80
1.40%
-1.73
시간 외 거래:
122.81
1.01
+0.83%
전일 마감가:
$123.53
열려 있는:
$123.33
하루 거래량:
1.10M
Relative Volume:
0.68
시가총액:
$17.99B
수익:
$9.61B
순이익/손실:
$1.62B
주가수익비율:
11.00
EPS:
11.07
순현금흐름:
$1.77B
1주 성능:
+2.25%
1개월 성능:
-0.96%
6개월 성능:
-31.16%
1년 성능:
-44.00%
1일 변동 폭
$121.51
$123.53
1주일 범위
$116.63
$125.34
52주 변동 폭
$110.03
$238.00
Biogen Inc Stock (BIIB) Company Profile
명칭
Biogen Inc
전화
(781) 464-2000
주소
225 BINNEY STREET, CAMBRIDGE, MA
BIIB을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BIIB
Biogen Inc
|
121.80 | 17.99B | 9.61B | 1.62B | 1.77B | 11.07 |
|
LLY
Lilly Eli Co
|
821.46 | 737.81B | 49.00B | 11.11B | -1.27B | 12.29 |
|
JNJ
Johnson Johnson
|
155.00 | 370.90B | 89.33B | 21.81B | 18.57B | 8.99 |
|
ABBV
Abbvie Inc
|
196.07 | 340.25B | 57.37B | 4.20B | 17.83B | 2.35 |
|
NVO
Novo Nordisk Adr
|
69.12 | 277.97B | 42.09B | 14.65B | 10.11B | 3.2833 |
|
NVS
Novartis Ag Adr
|
113.08 | 222.45B | 53.22B | 12.86B | 14.85B | 6.39 |
Biogen Inc Stock (BIIB) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-04-28 | 다운그레이드 | HSBC Securities | Buy → Hold |
| 2025-04-04 | 다운그레이드 | Argus | Buy → Hold |
| 2025-02-11 | 개시 | Bernstein | Mkt Perform |
| 2025-01-02 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2024-12-20 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2024-12-16 | 다운그레이드 | Stifel | Buy → Hold |
| 2024-12-10 | 재개 | BofA Securities | Neutral |
| 2024-12-09 | 다운그레이드 | Jefferies | Buy → Hold |
| 2024-11-18 | 다운그레이드 | Needham | Buy → Hold |
| 2024-11-15 | 개시 | Wolfe Research | Peer Perform |
| 2024-11-14 | 개시 | Citigroup | Neutral |
| 2024-10-31 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2024-10-10 | 재개 | Raymond James | Mkt Perform |
| 2024-02-14 | 재확인 | Needham | Buy |
| 2024-02-14 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2024-01-24 | 다운그레이드 | UBS | Buy → Neutral |
| 2023-12-20 | 재개 | Cantor Fitzgerald | Overweight |
| 2023-12-07 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2023-09-06 | 개시 | HSBC Securities | Buy |
| 2023-07-27 | 개시 | Scotiabank | Sector Outperform |
| 2023-07-24 | 재확인 | UBS | Buy |
| 2023-05-01 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2023-04-17 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2022-10-26 | 업그레이드 | Goldman | Neutral → Buy |
| 2022-10-13 | 업그레이드 | Stifel | Hold → Buy |
| 2022-10-07 | 업그레이드 | Argus | Hold → Buy |
| 2022-09-28 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
| 2022-09-28 | 업그레이드 | Mizuho | Neutral → Buy |
| 2022-09-28 | 업그레이드 | Robert W. Baird | Neutral → Outperform |
| 2022-04-18 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2022-03-08 | 다운그레이드 | Stifel | Buy → Hold |
| 2022-03-03 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2022-02-04 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2022-02-04 | 재확인 | Barclays | Equal Weight |
| 2022-02-04 | 재확인 | BofA Securities | Neutral |
| 2022-02-04 | 재확인 | Cowen | Outperform |
| 2022-02-04 | 재확인 | Morgan Stanley | Overweight |
| 2022-02-04 | 재확인 | Needham | Buy |
| 2022-02-04 | 재확인 | Oppenheimer | Outperform |
| 2022-02-04 | 재확인 | RBC Capital Mkts | Sector Perform |
| 2022-02-04 | 재확인 | Robert W. Baird | Neutral |
| 2022-02-04 | 재확인 | Wedbush | Neutral |
| 2022-02-04 | 재확인 | Wells Fargo | Equal Weight |
| 2022-02-04 | 재확인 | Wolfe Research | Peer Perform |
| 2022-01-13 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2022-01-12 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2021-12-10 | 재개 | Raymond James | Mkt Perform |
| 2021-12-09 | 재개 | Wells Fargo | Equal Weight |
| 2021-12-06 | 개시 | Goldman | Neutral |
| 2021-11-19 | 개시 | BMO Capital Markets | Outperform |
| 2021-09-23 | 개시 | Needham | Buy |
| 2021-06-18 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2021-06-14 | 재확인 | Truist | Buy |
| 2021-06-11 | 업그레이드 | Bernstein | Mkt Perform → Outperform |
| 2021-06-10 | 업그레이드 | UBS | Neutral → Buy |
| 2021-06-08 | 업그레이드 | Atlantic Equities | Underweight → Neutral |
| 2021-06-08 | 재확인 | Barclays | Equal Weight |
| 2021-06-08 | 업그레이드 | Citigroup | Sell → Neutral |
| 2021-06-08 | 재확인 | H.C. Wainwright | Buy |
| 2021-06-08 | 재확인 | Jefferies | Buy |
| 2021-06-08 | 재확인 | Morgan Stanley | Overweight |
| 2021-06-08 | 재확인 | RBC Capital Mkts | Sector Perform |
| 2021-06-08 | 업그레이드 | Robert W. Baird | Underperform → Neutral |
| 2021-06-08 | 재확인 | Stifel | Buy |
| 2021-06-08 | 업그레이드 | William Blair | Mkt Perform → Outperform |
| 2021-06-07 | 업그레이드 | BofA Securities | Underperform → Neutral |
| 2021-06-07 | 업그레이드 | Cowen | Market Perform → Outperform |
| 2021-06-07 | 업그레이드 | Raymond James | Underperform → Mkt Perform |
| 2021-02-05 | 다운그레이드 | DZ Bank | Buy → Hold |
| 2021-01-29 | 업그레이드 | Stifel | Hold → Buy |
| 2020-11-10 | 업그레이드 | DZ Bank | Hold → Buy |
| 2020-11-09 | 다운그레이드 | Atlantic Equities | Neutral → Underweight |
| 2020-11-09 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2020-11-09 | 다운그레이드 | Cowen | Outperform → Market Perform |
| 2020-11-09 | 재확인 | H.C. Wainwright | Buy |
| 2020-11-04 | 업그레이드 | BofA Securities | Underperform → Neutral |
| 2020-11-04 | 업그레이드 | Jefferies | Hold → Buy |
| 2020-11-04 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2020-10-28 | 개시 | UBS | Neutral |
| 2020-07-27 | 업그레이드 | Morgan Stanley | Underweight → Overweight |
| 2020-06-22 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2020-06-22 | 재확인 | RBC Capital Mkts | Sector Perform |
| 2020-06-09 | 다운그레이드 | Bernstein | Outperform → Mkt Perform |
| 2020-04-23 | 다운그레이드 | Citigroup | Neutral → Sell |
| 2020-04-23 | 다운그레이드 | Raymond James | Mkt Perform → Underperform |
| 2020-03-31 | 개시 | Wolfe Research | Peer Perform |
| 2020-02-27 | 개시 | Barclays | Overweight |
| 2020-01-27 | 업그레이드 | Canaccord Genuity | Hold → Buy |
| 2019-12-13 | 업그레이드 | Credit Suisse | Underperform → Neutral |
| 2019-12-02 | 다운그레이드 | Robert W. Baird | Neutral → Underperform |
모두보기
Biogen Inc 주식(BIIB)의 최신 뉴스
Biogen (BIIB): JP Morgan Lowers Price Target But Maintains Neutral Rating | BIIB Stock News - GuruFocus
Spinocerebellar Ataxias Pipeline 2025: Comprehensive Clinical Trials and Therapies Analysis with Key MOA and ROA Insights by DelveInsight | Biogen Inc, BioXcel Corp, Celavie Biosciences, Ionis Pharma - Barchart.com
Spinocerebellar Ataxias Pipeline 2025: Comprehensive - openPR.com
JPMorgan Adjusts Price Target for Biogen (BIIB) Following Q1 Report | BIIB Stock News - GuruFocus
Oligonucleotide Delivery System Market Key Players Analysis - openPR.com
Red Biotechnology Market to Witness Remarkable Growth with - openPR.com
Biogen Inc. (NASDAQ:BIIB) Receives Average Rating of "Hold" from Analysts - MarketBeat
Voya Investment Management LLC Decreases Stock Holdings in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Biogen (NASDAQ:BIIB) Price Target Lowered to $187.00 at HC Wainwright - MarketBeat
Robert W. Baird Cuts Biogen (NASDAQ:BIIB) Price Target to $255.00 - MarketBeat
Biogen (NASDAQ:BIIB) Posts Earnings Results, Misses Estimates By $0.24 EPS - MarketBeat
Northern Trust Corp Has $237.05 Million Holdings in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Biogen Inc. (NASDAQ:BIIB) Shares Acquired by Integrated Wealth Concepts LLC - MarketBeat
Biogen Inc. (NASDAQ:BIIB) Position Trimmed by MML Investors Services LLC - MarketBeat
Schonfeld Strategic Advisors LLC Has $12.16 Million Stock Position in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Biogen First Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags - Yahoo Finance
Biogen Inc. (NASDAQ:BIIB) Q1 2025 Earnings Call Transcript - Insider Monkey
AQR Capital Management LLC Has $81.91 Million Stock Position in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Biogen (BIIB) Maintains Outperform Rating Despite Lowered Price Target | BIIB Stock News - GuruFocus
Biogen's Lean Pivot Attracts Renewed Investor Interest - Finimize
Biogen (BIIB): Canaccord Genuity Lowers Price Target to $220 | BIIB Stock News - GuruFocus
TD Cowen Adjusts Price Target on Biogen to $175 From $200 - marketscreener.com
Morgan Stanley Adjusts Price Target on Biogen to $146 From $152 - marketscreener.com
Biogen price target lowered to $146 from $152 at Morgan Stanley - TipRanks
Biogen price target lowered to $205 from $217 at RBC Capital - TipRanks
Oppenheimer Adjusts Biogen (BIIB) Price Target to Reflect Outloo - GuruFocus
BIIB: HC Wainwright & Co. Lowers Price Target for Biogen | BIIB Stock News - GuruFocus
Biogen (BIIB) Price Target Cut by RBC Capital Amid Positive Outl - GuruFocus
Biogen (BIIB) Maintains Rating, Price Target Lowered by Baird | - GuruFocus
Morgan Stanley Adjusts Price Target for Biogen (BIIB) After Q1 R - GuruFocus
Biogen (BIIB) Target Price Cut Amid Market Adjustments | BIIB St - GuruFocus
Biogen (BIIB) Maintains Hold Rating by Needham Analyst | BIIB St - GuruFocus
Biogen outlines growth strategy with LEQEMBI and SKYCLARYS advancements for 2025 - MSN
Biogen (BIIB) Price Target Reduced by Baird Analyst | BIIB Stock News - GuruFocus
Biogen (BIIB) Price Target Reduced by Canaccord Despite Strong Q - GuruFocus
Biogen (BIIB) Price Target Reduced by Canaccord Despite Strong Q1 Performance | BIIB Stock News - GuruFocus
Lido Advisors LLC Raises Stock Holdings in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Biogen Easily Tops Earnings Forecasts As Leqembi, Skyclarys Sales Soar - MSN
The Zacks Analyst Blog Highlights: Encana, Enbridge, BankAtlantic Bancorp, BB&T and Biogen IdecPress Releases - ADVFN
Decoding Biogen Inc (BIIB): A Strategic SWOT Insight - GuruFocus
Biogen Inc (BIIB) Q1 2025 Earnings Call Highlights: Strong Revenue Growth Amidst MS Franchise ... - Yahoo Finance
Quarry LP Buys New Shares in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Aquatic Capital Management LLC Buys 10,845 Shares of Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Biogen Inc (BIIB) Q1 2025 Earnings Call Highlights: Strong Reven - GuruFocus
Biogen reports Q1 EPS $3.02, consensus $2.96 - TipRanks
Biogen Inc. Reports Strong Q1 2025 Results - TipRanks
Biogen’s Manufacturing Sites, Revenue Sources Protect It From Big Tariff Impact - insights.citeline.com
Unveiling Biogen (BIIB) Q1 Outlook: Wall Street Estimates for Key Metrics - MSN
Biogen Inc. Earnings Call Highlights Growth and Challenges - TipRanks
SEC Form S-3ASR filed by Biogen Inc. - Quantisnow
Biogen (BIIB) Boosted by New Products as Revenue Climbs - GuruFocus
Biogen Inc (BIIB) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.53%
자본화:
|
볼륨(24시간):